Felodipine, an anti-hypertensive agent that is exclusively a CYP3A4 substrate, has been demonstrated to cause changes in sorafenib pharmacokinetic parameters in an 80-year-old HCC patient with hypertension [116]. The gene discussed is CYP3A4; the disease is hepatocellular carcinoma.